AlloVir
General Information | |
Business: |
We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. Our innovative and proprietary virus-specific T cell, or VST, therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. To date, we have generated five innovative, allogeneic, off-the-shelf VST therapy candidates targeting 12 different devastating viruses, the most advanced of which has successfully completed a proof-of-concept trial across five viruses and is entering initial pivotal trials for the treatment of virus-associated hemorrhagic cystitis in the fourth quarter of 2020. |
Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Employees: | 21 |
Founded: | 2014 |
Contact Information | |
Address | 139 Main Street, Suite 500, Cambridge, MA 02142, US |
Phone Number | 617-433-2605 |
Web Address | https://www.AlloVir.com |
View Prospectus: | AlloVir |
Financial Information | |
Market Cap | $1065.4mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-30.7 mil (last 12 months) |
IPO Profile | |
Symbol | ALVR |
Exchange | NASDAQ |
Shares (millions): | 16.3 |
Price range | $17.00 - $17.00 |
Est. $ Volume | $276.3 mil |
Manager / Joint Managers | Morgan Stanley/ J.P. Morgan/ SVB Leerink/ Piper Sandler |
CO-Managers | - |
Expected To Trade: | 7/30/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |